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ABSTRACT 
In continuation of our endeavor towards the design and development of potent and effective antimicrobial 
agents, three series of phthalimide derivatives (4a–i, 5a–f, and 6a-c) were synthesized, fully characterized and 
evaluated for their potential antibacterial, antifungal and antimycobacterial activities. These efforts led to the 
discovery of nine compounds 4c, 4f, 4g, 4h, 4i, 5c, 5d, 5e, and 6c (MIC range from 0.49 to 31.5 μg/mL) with po-
tent antibacterial, antifungal, and antimycobacterial activities. Ampicillin, ciprofloxacin, amphotericin B were 
used as references for antibacterial and antifungal screening respectively, while isoniazid was used as a reference 
for antimycobacterial testing. Furthermore, molecular modeling studies were done to explore the binding mode 
of the most active derivatives to M. tuberculosis enoyl reductase (InhA) and DNA gyrase B. Our study showed 
the importance of both hydrogen bonding and hydrophobic interactions as a key interaction with the target en-
zymes. 
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1. INTRODUCTION 
In recent years, microbial infections are 
associated with high rates of attributable 
morbidity and mortality. Infections caused 
by microbial species are common in immune 
compromised patients and have significant 
treatment costs and mortality (Appelbaum 
and Hunter, 2000; Ball, 2000). The increas-
ing rate of bacterial resistance to clinical an-
timicrobial agents and its impact on the 
treatment of infectious diseases have begun 
to present a unique problem throughout the 
world. Drug resistant, multiple drug resistant 
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(MDR), and extensively drug resistant 
(XDR) to infectious bacterial pathogens put 
a greater risk on the population at large due 
to the risk of pandemic illness (Frere, 1995). 
Increasing complication is the fact that many 
antibacterial agents can induce mutations and 
resistance, often by different mechanisms 
(Yang et al., 2001; Yu et al., 2009). The 
most infectious bacteria of resistant types are 
Methicillin-resistant Staphylococcus aureus 
(MRSA) and vancomycin-resistant Entero-
coccus (VRE) that have been present largely 
in hospitals (Blomquist, 2006). The 
phthalimide subunit has been described as a 
privileged scaffold to design new lead drug-
candidates of different biological activities 
and applied for management of different dis-
eases like leprosy, AIDS, tumor, diabetes, 
multiple myeloma, convulsion, inflamma-
tion, pain, and bacterial infection (Kamal et 
al., 2006, Santos et al., 2009). The literature 
survey showed the antimicrobial potential of 
phthalimide derivatives which possess min-
imal inhibitory concentrations (MICs) com-
parable with those of clinically used antibiot-
ics (Orzeszko et al., 2002). In general, the 
state of the art was reported that phthalimide 
ring represents a very important privileged 
substructure in organic synthesis for prepar-
ing diverse biologically active molecules 
(Couture et al., 1998, 2000; El-Gohary and 
Shaaban, 2015; Gupta et al., 2016; Guzior et 
al., 2015; Hoarau et al., 2000). Typically, the 
most important pharmacological effects that 
have been reported for phthalimide deriva-
tives are anti-cancer (Kamal et al., 2013), an-
ti-microbial (Amin et al., 2013), anti-oxidant 
(El-Gaby et al., 2000), anti-inflammatory 
(Rajasekaran et al., 2011) and analgesic ac-
tivities (Pophale and Deodhar, 2010). The 
chemical structure of phthalimides (-CO-
N(R)-CO-) is mainly hydrophobic which in-
creases their potential to pass different in vi-
vo biological barriers (Bansode et al., 2009). 
Certain studies had synthesized novel deriva-
tives of phthalimide showing potent antimy-
cobactetial activity (Lamie et al., 2015; 
Santos et al., 2009). Our recent work report-
ed that novel compounds by molecular hy-
bridization of the phthalimide ring with aro-
matic structures through –CH=N linker were 
potent antimicrobial agents compared to 
clinical used antibiotics (Ahmed et al., 
2016). The presence of highly active refer-
ence compounds (A-G) bearing of 
phthalimide scaffold (Figure 1), connected to 
different side chain of different properties 
having a variety of anticancer and antimicro-
bial activities profile, SAR analysis was 
done for these group of compounds for fur-
ther work (Collin et al., 2001, Norman et al., 
1996, Ravi, 2013). Consequently, the chance 
to increase the biological activity of 
phthalimide derivatives occurs through a 
practical molecular hybridization approach 
by introduction of different pharmacophore 
subunits connected directly to the acidic im-
ide nitrogen with or without linkers were 
persuaded. In our study, incorporation of ar-
omatic or heteroaromatic structures with dif-
ferent substituents through 1 or 2 carbon 
linker was done and resulted in novel com-
pounds with improved antibacterial and an-
timycobactrial properties. 
 
Figure 1: Reference drugs. Candidate drugs 
(A-G) bearing phthalimide substructure having 
different biological activities 
 
 
2. STUDY RATIONALE AND DESIGN 
The ring phthalimide is considered as a 
stable here aromatic cyclic structure with 
variable pharmacological interest 
(Raghunadh et al., 2013). The effective 
mechanism of published derivatives is still 
unclear and needs more research for SAR in-
terpretation (Ahmed et al., 2016). Hence, the 
good way for designing of phthalimide-
based novel compounds are made by molec-
ular hybridization techniques. In our study, 
we combined the ring phthalimide through 
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carbonyl or acetyl linker with heteroaryl 
structures containing nitrogen, sulphur, or 
halogen atoms (Figure 2). 
 
 
Figure 2: Rationale design of target com-
pounds. Target compounds with variable side 
chains showing functional moieties bonded to 
phthalimide ring 
 
 
3. MATERIALS AND METHODS 
3.1 Chemistry 
Materials and Instrumentation  
Chemicals and solvents were purchased 
from Sigma-Aldrich (Canada) and Alfa Ae-
sar, and were used as received. Melting 
points were determined in open capillaries 
using an electrothermal apparatus and are 
uncorrected. The progress of the reactions 
was monitored using thin layer chromato-
graphy (TLC) on Merck silica gel 60 F254 
plates. Infrared (IR) spectra were recorded 
using Bruker Alpha FT-IR Spectrometer as 
pressed KBr pellets. 1H-NMR and 13C-NMR 
spectra were displayed using a 300 MHz and 
at 75 MHz, respectively, on a Bruker Avance 
Spectrometer in DMSO-d6 with internal 
standard tetramethylsilane. Elemental anal-
yses for C, H and N were performed using an 
Exeter Analytical, Inc. CE-440 Elemental 
Analyzer. 
General procedure for the synthesis of 2-
(1,3-dioxoisoindolin-2-yl)acetamide  
derivatives (4a-i) 
Triethylamine (1.1 equivalent amount) 
was added to a solution of amine member 1 
(equivalent amount) in dry CH3CN (10 mL). 
The resulting mixture was stirred for 15 min 
and then treated with chloroacetyl chloride 
reagent (1.1 equivalent amount) dissolved in 
dry CH3CN (5 mL) drop-wise and the result-
ing mixture was stirred for 2 h at room tem-
perature. The reaction mixture was cooled, 
poured into ice-cold water (50 ml) contain-
ing a 5 drops of 10 % dilHCl and stirred until 
the solid separated. Crude product was fil-
tered. The chloroacetamides were added to a 
solution of phthalimide 2 in acetone/K2CO3 
mixture, stirred for 20 minutes followed by 
reflux at 100 °C solvent for 3 hours. After 
completion of the reaction (monitored by 
TLC), the mixture was kept at room tem-
perature and poured into ice-cold water 
(50 ml) and stirred until the solid separated. 
The formed solid product was collected by 
filtration. 
N-benzyl-2-(1,3-dioxoisoindolin-2-
yl)acetamide (4a) 
IR (vmax/cm): 3060-2855 (N-H), 1780 
and 1715 (2C=O), 1661 (N-H-C=O); 1H 
NMR (300 MHz, d6-DMSO): 8.8 (bs, 1H, N-
H), 8.3–7.5 (m, 4H, H-phthalimide) 7.1–6.8 
(m, 5H, H-Ar), 4.7 (s, 2H, CH2-C=O), 4.4 (s, 
2H, NH-CH2); 13CNMR (300 MHz, d6-
DMSO) δ 168.7, 168.2, 139.9, 132.2, 128.4, 
127.6, 126.8, 125.5, 44.6, 43.8; (Found C, 
69.20; H, 4.73; N, 9.50; C14H14N2O5, re-
quires C, 69.38; H, 4.79; N, 9.52). 
N-(4-chlorobenzyl)-2-(1,3-dioxoisoindolin-
2-yl)acetamide (4b) 
IR (vmax/cm): 3060-2855 (N-H), 1775 
and 1710 (2C=O), 1667 (N-H-C=O); 1H 
NMR (300 MHz, d6-DMSO): 8.8 (bs,1H,N-
H), 8.0–7.9 (m, 4H, H-phthalimide) 7.8–6.8 
(m, 4H, H-Ar), 4.5 (s, 2H, CH2-C=O), 4.2 (s, 
2H, N-H-CH2); 13CNMR (300 MHz, d6-
DMSO) δ 168.7, 168.2, 139.0, 136.7, 131.6, 
129.9, 129.5, 128.5, 128.0, 42.3, 42.7; 
(Found C, 62.10; H, 3.89; N, 8.36; 
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C16H13ClN2O3, requires C, 62.11; H, 3.99; N, 
8.52). 
2-(1,3-dioxoisoindolin-2-yl)-N-(4-
hydroxybenzyl)acetamide (4c) 
IR (vmax/cm): 3300-2860 (O-H), 3060-
2855 (N-H), 1785 and 1716 (2C=O), 1661 
(N-H-C=O); 1H NMR (300 MHz, d6-
DMSO): 9.4 (bs,1H,O-H), 8.3 (bs,1H,N-H), 
8.0–7.9 (m, 4H, H-phthalimide) 7.8–6.8 (m, 
4H, H-Ar), 4.5 (s, 2H, CH2-C=O), 4.2 (s, 2H, 
N-H-CH2); 13CNMR (300 MHz, d6-DMSO) 
δ 168.7, 168.2, 157.2, 134.9, 131.9, 129.5, 
127.4, 123.5, 115.7, 40.9; (Found C, 65.75; 
H, 4.50; N, 9.01; C17H14N2O4, requires C, 
65.80; H, 4.55; N, 9.03). 
2-(1,3-dioxoisoindolin-2-yl)-N-(4-
methoxybenzyl)acetamide (4d) 
IR (vmax/cm): 3060-2855 (N-H), 1779 
and 1717 (2C=O), 1668 (N-H-C=O);1H 
NMR (300 MHz, d6-DMSO): 8.8 (bs,1H,N-
H), 8.0–7.9 (m, 4H, H-phthalimide) 7.8–6.8 
(m, 4H, H-Ar), 4.5 (s, 2H, CH2-C=O), 4.2 (s, 
2H, NH-CH2), 3.7 (s, 3H, O-CH3); 13CNMR 
(300 MHz, d6-DMSO) δ 168.7, 168.2, 159.0, 
134.9, 131.9, 129.4, 129.0, 123.6, 114.4, 
55.5, 40.8, 40.2; (Found C, 66.45; H, 4.73; 
N, 8.45; C18H16N2O4, requires C, 66.66; H, 
4.96; N, 8.64). 
2-(1,3-dioxoisoindolin-2-yl)-N-(4-
methylbenzyl)acetamide (4e) 
IR (vmax/cm): 3065-2850 (N-H), 1775 
and 1718 (2C=O), 1675 (N-H-C=O); 1H 
NMR (300 MHz, d6-DMSO): 9.0 (bs,1H,N-
H), 8.0–7.9 (m, 4H, H-phthalimide) 7.8–6.8 
(m, 4H, H-Ar), 4.5 (s, 2H, CH2-C=O), 4.2 (s, 
2H, N-H-CH2), 2.2 (s, 3H, CH3); 13CNMR 
(300 MHz, d6-DMSO) δ 168.1, 163.1, 160.7, 
134.9, 133.3, 133.1, 131.9, 130.1, 123.6, 
115.9, 115.6, , 42.7, 41.0, 21.3; (Found C, 
70.05; H, 5.20; N, 9.05; C18H16N2O3, re-
quires C, 70.12; H, 5.23; N, 9.09). 
2-(1,3-dioxoisoindolin-2-yl)-N-(4-
fluorobenzyl)acetamide (4f) 
IR (vmax/cm): 3065-2850 (N-H), 1780 
and 1720 (2C=O), 1665 (N-H-C=O); 1H 
NMR (300 MHz, d6-DMSO): 8.3 (bs,1H,N-
H), 8.0–7.9 (m, 4H, H-phthalimide) 7.8–6.8 
(m, 4H, H-Ar), 4.5 (s, 2H, CH2-C=O), 4.2 (s, 
2H, N-H-CH2); 13CNMR (300 MHz, d6-
DMSO) δ 168.6, 168.1, 137.1, 136.8, 136.7, 
136.1, 135.0, 134.1, 131.9, 129.8, 129.5, 
129.2, 128.1, 127.9, 127.6, 123.6, 42.7, 41.0; 
(Found C, 65.75; H, 4.50; N, 9.01; 
C17H13FN2O4, requires C, 65.38; H, 4.20; N, 
8.97). 
2-(2-(1,3-dioxoisoindolin-2-
yl)acetamido)butanoic acid (4g) 
IR (vmax/cm): 3200-2950 (O-H), 3246-
2865 (N-H), 1745 (C=O-OH), 1675 (N-H-
C=O), 1690 and 1660 (2C=O); 1H NMR 
(300 MHz, d6-DMSO): 8.5 (bs, 1H, O-H), 
7.8-7.5 (m, 4H, ArH 4Hs phthalimide), 4.9 
(s, 1H, N-H), 4.6 (s, 2H, CH2-C=O), 4.3 (t , 
1H, J = 5.6, N-H-CH-C=O), 1.9 (q, 2H, J = 
5.6, CH-CH2-CH3), 1.1 (t, 3H, J = 5.6, CH3); 
13CNMR (300 MHz, d6-DMSO) δ 175.6, 
168.7, 132.7, 132.0, 126.5, 54.85, 44.40, 
26.35, 11.1; (Found C, 57.70; H, 4.65; N, 
9.43; C14H14N2O5, requires C, 57.93; H, 
4.86; N, 9.65). 
(2-(1,3-dioxoisoindolin-2-yl)acetyl)leucine 
(4h) 
IR (vmax/cm): 3200-2960 (O-H), 3236-
2855 (N-H), 1755 (C=O-OH), 1675 (N-H-
C=O), 1689 and 1665 (2C=O); 1H NMR 
(300 MHz, d6-DMSO): 8.6 (bs, 1H, O-H), 
7.7-7.5 (m, 4H, 4Hs phthalimide), 4.7 (s, 1H, 
N-H), 4.5 (s, 2H, CH2-C=O), 4.1 (t , 1H, J = 
5.6, N-H-CH-C=O), 1.8 (m, 2H, CH-CH2-
CH), 1.6 (m, 1H, CH3-CH-CH3), 1.1(s , 6H, 
CH3); 13CNMR (300 MHz, d6-DMSO) δ 
175.4, 168.7, 132.2, 132.1, 126.5, 50.7, 44.4, 
40.2, 26.4, 23.1; (Found C, 60.15; H, 5.65; 
N, 8.73; C16H18N2O5, requires C, 60.37; H, 
5.70; N, 8.80). 
  
EXCLI Journal 2016;15:781-796 – ISSN 1611-2156 
Received: September 20, 2016, accepted: November 01, 2016, published: December 06, 2016 
 
 
785 
2-(2-(1,3-dioxoisoindolin-2-
yl)acetamido)hexanoic acid (4i) 
IR (vmax/cm): 3200-2950 (O-H), 3246-
2865 (N-H), 1745 (C=O-OH), 1675 (N-H-
C=O), 1690 and 1660 (2C=O); 1H NMR 
(300 MHz, d6-DMSO): 8.6 (bs, 1H, O-H), 
7.8-7.5 (m, 4H, 4Hs phthalimide), 4.8 (s, 1H, 
N-H), 4.6 (s, 2H, CH2-C=O), 4.3 (t , 1H, J = 
5.6, N-H-CH-C=O), 1.8 (m, 2H, CH-CH2-
CH), 1.4 (m, 2H, CH2-CH2-CH3), 1.2 (m, 
2H, CH2-CH2-CH2), 1.6 (m, 1H, CH3-CH-
CH3), 1.1(s , 3H, CH3); 13CNMR (300 MHz, 
d6-DMSO) δ 175.5, 168.7, 132.2, 132.1, 
126.5, 54.1, 44.4, 31.3, 29.4, 23.4, 14.1; 
(Found C, 60.35; H, 5.56; N, 8.63; 
C16H18N2O5, requires C, 60.37; H, 5.70; N, 
8.80). 
General procedure for the synthesis of 2-
Acyl and sulfonyl isoindoline-1,3-dione  
derivatives (5a-f) 
The corresponding acid or sulphonyl 
chloride (equivalent amount) was added 
dropwise to a solution of phthalimide 2 in 
DMF/TEA mixture in ice, stirred for 1 hour 
at 60 °C 3 hours. After completion of the re-
action (monitored by TLC), the mixture was 
kept at room temperature and poured into 
ice-cold water (50 ml) and stirred until the 
solid separated. The formed solid product 
was collected by filtration, washed, recrystal-
lized from methanol and hexane to yield 5a-
f.   
2-((4-phenoxyphenyl)sulfonyl)isoindoline-
1,3-dione (5a) 
IR (vmax/cm): 1781 and 1718 (2C=O), 
1340 and 1145 (SO2); 1H NMR (300 MHz, 
d6-DMSO) δ 8.1-7.1 (m, 13H, ArH (4Hs 
benzyl+4Hs phthalimide+5Hs phenoxy); 
13CNMR (300 MHz, d6-DMSO) δ 163.4, 
163.0, 160.2, 154.6, 136.3, 133.4, 131.8, 
131.3, 131.2, 131.1, 130.9, 130.8, 130.6, 
128.9, 128.5, 125.9, 125.1, 124.7, 1219, 
120.2, 118.1, 117.9; (Found C, 63.15; H, 
3.25; N, 3.60; C20H13NO5S, requires C, 
63.32; H, 3.45; N, 3.69). 
2-((4-isopropylphenyl)sulfonyl)isoindoline-
1,3-dione (5b) 
IR (vmax/cm): 1775 and 1720 (2C=O), 
1345 and 1155 (SO2); 1H NMR (300 MHz, 
d6-DMSO) δ 8.7-6.9 (m, 8H, ArH (4Hs ben-
zyl+4Hs phthalimide), 3.1 (s, 1H, CH), 1.2 
(s, 6H, CH3); 13CNMR (300 MHz, d6-
DMSO) δ 166.2, 152.8, 140.7, 135.1, 131.6, 
130.1, 128.2, 127.2, 126.1, 34.2, 23.4; 
(Found C, 61.95; H, 4.54; N, 4.20; 
C17H15NO4S, requires C, 61.99; H, 4.59; N, 
4.25) 
2-(4-methylpiperazine-1-
carbonyl)isoindoline-1,3-dione (5c) 
IR (vmax/cm): 1701 and 1678 (3C=O); 1H 
NMR (300 MHz, d6-DMSO) δ 7.8-7.5 (m, 
4H, 4Hs phthalimide), 3.6-3.3 (m, 4H, N-
CH2-CH2), 2.8-2.6 (m, 4H, CH2-CH2-N-
CH3), 2.3(s , 3H, CH3); 13CNMR (300 MHz, 
d6-DMSO) δ 170.8, 168.7, 132.2, 132.1, 
126.5, 52.6, 46.0; (Found C, 61.45; H, 5.46; 
N, 15.25; C14H15N3O3, requires C, 61.53; H, 
5.53; N, 15.38). 
2-(2-chloroisonicotinoyl)isoindoline-1,3-
dione (5d) 
IR (vmax/cm): 1701 and 1678 (3C=O); 1H 
NMR (300 MHz, d6-DMSO) δ 8.7–8.1 (m, 
3H, Pyridin-H), 7.9–7.2 (m, 4H, 
Phthalimide); 13CNMR (300 MHz, d6-
DMSO) δ 169.8, 167.7, 151.2, 150.4, 139.7, 
134.6, 131.9, 124.5, 122.5, 121.2; (Found C, 
58.61; H, 2.36; N, 9.75; C14H7ClN2O3, re-
quires C, 58.66; H, 2.46; N, 9.77). 
2-(5-nitrofuran-2-carbonyl)isoindoline-1,3-
dione (5e) 
IR (vmax/cm): 1691 and 1688 (3C=O); 1H 
NMR (300 MHz, d6-DMSO) δ 7.9–7.6 (m, 
4Hs, Phthalimide), 7.5–7.2 (m, 2Hs, furoyl); 
13CNMR (300 MHz, d6-DMSO) δ 181.9, 
168.7, 154.8, 151.4, 132.2, 132.1, 126.5, 
125.5, 115.4; (Found C,54.50; H, 2.10; N, 
9.75; C13H6N2O6, requires C, 54.56; H, 2.11; 
N, 9.79). 
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2-(furan-2-carbonyl)isoindoline-1,3-dione 
(5f) 
IR (vmax/cm): 1685 and 1678 (3C=O); 1H 
NMR (300 MHz, d6-DMSO) δ 7.9–7.6 (m, 
4Hs, Phthalimide), 7.2–6.6 (m, 3Hs, furoyl); 
13CNMR (300 MHz, d6-DMSO) δ 183.0, 
168.7, 152.8, 144.0, 132.2, 132.1, 126.5, 
120.9, 112.6; (Found C, 64.67; H, 2.80; N, 
5.75; C13H7NO4, requires C, 64.73; H, 2.93; 
N, 5.81). 
General procedure for the synthesis of 2-
Alkynylylisoindoline-1,3-dione derivatives 
(6a-c) 
To a mixture of phthalimide 2 (equiva-
lent amount) and K2CO3 in acetone (15 ml), 
alkynyl halide (equivalent amount) was add-
ed with continuous stirring at room tempera-
ture for 1 hr. The reaction was refluxed at 
100 °C for 2 hours. After ending of the reac-
tion (monitored by TLC), the mixture was 
kept at room temperature and poured into 
ice-cold water (50 ml) and stirred until the 
solid formed. The solid product was filtered, 
washed, recrystallized from ethyl acetate/ 
hexane to yield 6a-c.   
2-(but-3-yn-1-yl)isoindoline-1,3-dione (6a) 
IR (vmax/cm): 1695 and 1670 (2C=O); 1H 
NMR (300 MHz, d6-DMSO) δ 7.9–7.8 (m, 
4Hs, Phthalimide), 3.7 (m, 2H, N-CH2), 2.8 
(m, 2H, CH2-C), 1.9 (s, 1H, =CH); 13CNMR 
(300 MHz, d6-DMSO) δ 168.0, 135.0, 131.9, 
123.6, 81.3, 73.2, 36.6, 17.9; (Found C, 
72.22; H, 4.10; N, 6.97; C13H9NO2, requires 
C, 72.35; H, 4.55; N, 7.03). 
2-(pent-4-yn-1-yl)isoindoline-1,3-dione (6b) 
IR (vmax/cm): 1694 and 1678 (2C=O); 1H 
NMR (300 MHz, d6-DMSO): 7.9–7.8 (m, 
4Hs, Phthalimide), 3.6 (m, 2H, N-CH2), 2.7 
(t, 2H, J = 5.6, CH2-C), 1.8 (s, 1H, -CH), 1.7 
(m , 2H, CH2-CH2-CH2); 13CNMR (300 
MHz, d6-DMSO) δ 168.4, 134.7, 132.1, 
123.4, 123.1, 84.1, 71.9, 27.2, 16.1; (Found 
C, 73.20; H, 5.10; N, 6.45; C13H11NO2, re-
quires C, 73.23; H, 5.20; N, 6.57). 
 
2-(pent-2-yn-1-yl)isoindoline-1,3-dione (6c) 
IR (vmax/cm): 1697 and 1688 (2C=O); 1H 
NMR (300 MHz, d6-DMSO): 7.9–7.8 (m, 
4Hs, Phthalimide), 4.3 (m, 2H, CH2-C), 2.1 
(m, 2H, C-CH2), 1.0 (t, 3H, J = 5.6, CH3); 
13CNMR (300 MHz, d6-DMSO) δ 167.3, 
135.1, 131.8, 123.9, 84.8, 74.2, 27.4, 13.9, 
11.6; (Found C, 73.13; H, 5.06; N, 6.25; 
C13H11NO2, requires C, 73.23; H, 5.20; N, 
6.57). 
 
3.2 Biological evaluation 
Antimicrobial activity 
All microbial strains used in this study 
were imported from culture collection of the 
Regional Center for Mycology and Biotech-
nology (RCMB), Al-Azhar University, Cai-
ro, Egypt. The inhibition zones are intro-
duced as diameter measure of growth inhibi-
tion by using of agar well diffusion method. 
This method is described by applying holes 
(1 cm diameter) in the agar layer using ster-
ile cork borer in sterile malt agar plates for 
fungi and sterile nutrient agar plates for bac-
teria that formerly and uniformly seeded 
with tested microorganisms. The holes were 
filled by 100 μL fungal filtrates. A cooled 
incubation process was applied for the plates 
at 4 °C for one hour to enable diffusion and 
then incubated at 37 °C and 28 °C degrees 
for tested bacteria and fungi respectively. In-
hibition zones developed were measured af-
ter 24 h of incubation for bacteria and 48 h 
of incubation for fungi. Different reference 
antibiotics were used like ampicillin, ampho-
tericin B and ciprofloxacin as positive con-
trol. The experiment was performed in tripli-
cate taking the average of zone of inhibition 
(Cappuccino and Sherman, 1999; Vanden-
Berghe and Vlientinck, 1991). 
Minimum Inhibitory Concentration 
MIC was demonstrated by a serial dilu-
tion technique starting with 100 mmol con-
centration of all compounds dissolved in 
1 mL DMSO and then reduced by successive 
twofold dilution of stock solution using a 
calibrated micropipette (Irobi et al., 1996). 
Ampicillin, ciprofloxacin, and amphotericin 
EXCLI Journal 2016;15:781-796 – ISSN 1611-2156 
Received: September 20, 2016, accepted: November 01, 2016, published: December 06, 2016 
 
 
787 
B were used as reference compounds for 
bacteria and fungi respectively. The final so-
lutions concentrations were 125, 62.50, 
31.25, 15.63, 7.81, 3.90, 1.95, 0.98, 0.49, 
0.24 and 0.12 μM/mL. The microtiter plates 
were incubated at 37 °C for tested bacteria 
and 28 °C for tested fungi and were recorded 
using microplate reader after 24 h for bacte-
ria and after 48 h for fungi. In each case, 
triplicate tests were performed and the aver-
age was taken as final reading. MIC was de-
fined as the lowest concentration inhibiting 
test organism’s growth (Urzua et al., 1998). 
Antimycobacterial activity 
M. tuberculosis (RCMB 010126) strain 
was provided from culture collection of the 
Regional Centre for Mycology and Biotech-
nology (RCMB), Al-Azhar University, Cai-
ro, Egypt. The isolated M. tuberculosis 
(RCMB 010126) clone was cultivated under 
agitation on LB medium at 37 °C for 24 h. 
The antitubercular activity was expressed as 
the diameter of inhibition zones using agar 
well diffusion method and determination of 
MIC using serial dilution technique. Isonia-
zid was used as a reference drug. The final 
solution concentrations were 125, 62.50, 
31.25, 15.63, 7.81, 3.90, 1.95, 0.98, 0.49, 
0.24 and 0.12 μM/mL. The zones of inhibi-
tion were analysed after 72 h of incubation at 
37 °C. Each test was repeated 3 times. MIC 
was expressed as the lowest concentration 
inhibiting test organism’s growth (Abdel-
Aziz et al., 2015). 
 
3.3 Molecular docking 
Molecular docking of target compounds 
into the three-dimensional complex of prom-
ising biological targets including the crystal 
structures of E. coli topoisomerase II DNA 
gyrase B (PDB code 1KZN) as bacterial 
promising target and crystal structure of M. 
tuberculosis enoyl reductase (InhA) (PDB 
code 4TZK) as TB promising target (Berman 
et al., 2000) was carried out using the Auto-
Dock software package (version 4.0) as im-
plemented through the graphical user inter-
face AutoDockTools (ADT) (Morris et al., 
1998). Before the run of experiments, the 
water and ligand molecules were removed 
from the X-ray structure of the protein. In 
addition, polar hydrogen atoms were added 
to the structure with the MOE software 
(Molecular Operating Environment (MOE) 
Chemical Computing Group) (MOE, 2012) 
and atomic partial charges were calculated 
using AutoDock Tools. The target active 
compounds were docked into the active site 
of enzymes for prediction of compound 
binding modes. Finally, high-scoring binding 
poses were selected on the basis of visual in-
spection. 
 
4. RESULTS AND DISCUSSION 
Straightforward synthetic procedures 
were adopted for the synthesis of our target 
compounds. Chloroacetylation of benzyla-
mine 1 and chloroacetyl chloride resulted in 
amine acyl chloride derivatives 2 which were 
further reacted with the phthalimide ring 3 
producing the novel target compounds 4a-i, 
(Figure 3). 
 
Figure 3: Synthesis of compounds 4a–i. Rea-
gents and conditions are reported 
 
 
While the products 5a-f were prepared 
via reaction of heteroaryl carbonyl chlorides 
or sulphonyl chlorides with phthalimide ring 
under reflux for 3–4 h in DMF-TEA mixture 
(Figure 4).  
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Figure 4: Synthesis of compounds 5a–f. Rea-
gents and conditions are reported 
 
 
On the other hand, the compounds 6a-c 
were prepared via reaction of alkynyl bro-
mides with phthalimide ring under reflux for 
3–4 h in acetone/potassium carbonate mix-
ture at 50 °C (Figure 5). 
 
Figure 5:  Synthesis of compounds 6a–c. Rea-
gents and conditions are reported 
 
 
Primary checking of the synthesized 
compounds purity was done by thin layer 
chromatography (TLC). Furthermore, all the 
synthesized compounds were characterized 
by spectroscopic techniques (1H-NMR, 13C-
NMR and elemental analysis). The obtained 
spectral data of the synthesized compounds 
were in agreement with their proposed struc-
tures. All synthesized compounds showed 
the stretching bands for the two carbonyl of 
the phthalimide ring. For compounds (4a-f) 
the IR data of these compounds clearly 
showed additional C=O stretching band ~ 
around 1660 cm-1 which corresponds to the 
carbonyl group of the side chain. Com-
pounds (4g-i) showed additionally the OH 
band around 2950-3200 cm-1 and additional 
carbonyl of the carboxylic acid around 
1750 cm-1. The sulfonyl group in compound 
(5a-b) around at 1340 cm-1 and 1150 cm-1. 
The nuclear magnetic resonance spectra (1H 
NMR) of all synthesized compounds showed 
multiple signals corresponding to resonances 
of aromatic phthalimide protons at 7.9–8.0 
ppm range and the other phenyl ring protons 
connected to phthalimide subunit at 7.6 ppm 
and 8.0 ppm. While 13CNMR of the com-
pounds showed the signals corresponding to 
resonances of phthalimide protons at 123.7, 
134.8, 131.4, and 166.2 ppm. The 13CNMR 
showed the signals of carbon resonance of 
phenyl ring linked to phthalimide subunit at 
132, 126, 128, and 137 ppm. Physical prop-
erties of target compounds are reported in 
Table 1. 
 
 
Table 1: Physical properties of synthesized 
compounds including molecular weight, yield, 
and melting points reports 
Cps. Molecular 
Weight 
Yield (%) Melting 
Point (CO) 
4a 294.30 82 251-253 
4b 328.75 79 301-303 
4c 310.30 88 257-259 
4d 324.33 78 260-262 
4e 308.33 90 290-290 
4f 312.30 74 305-307 
4g 290.27 65 141-143 
4h 318.32 60 130-132 
4i 318.12 62 125-127 
5a 379.39 68 160-162 
5b 329.37 70 182-184 
5c 273.29 67 350-352 
5d 286.67 78 320-322 
5e 286.20 84 309-311 
5f 241.20 77 320-321 
6a 199.21 62 282-284 
6b 213.23 68 268-270 
6c 213.23 71 247-249 
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4.1 Biology 
All the newly synthesized compounds 
were screened for their antibacterial and anti-
fungal activities via agar diffusion well 
method (Vanden-Berghe and Vlientinck, 
1991). The minimum inhibitory concentra-
tions (MIC) were determined by serial dilu-
tion method (Vanden-Berghe and Vlientinck, 
1991). Four Gram-positive bacteria includ-
ing Streptococcus Pneumoniae (RCMB 
010010), Bacillus Subtilis (RCMB 010067), 
and Staphylococcus Aureus (RCMB 
000106); three Gram-negative bacteria in-
cluding Pseudomonas Aeruginosa (RCMB 
010043), Escherichia Coli (RCMB 010052), 
and Salmonella Typhimurium (RCMB 
000106); three fungi including Aspergillus 
Fumigatus (RCMB 02568), Syncephalas-
trum Racemosum (RCMB 05922), Geotri-
cumCandidum (RCMB 05097), and Candida 
Albicans (RCMB 05036); and one Mycobac-
terium Tuberculosis (RCMB 010126) were 
used for presenting of the activity of the 
newly synthesized compounds. Ampicillin, 
ciprofloxacin, isoniazid, and amphotericin B 
drugs were used as control drugs (Atta-ur-
Rahman and Thomsen, 2001; Smania et al., 
1999). The observed inhibition zone (IZ) and 
MIC data of both tested compounds and ref-
erence drugs are given in Table 2 and Figure 
6. In general, the obtained biological data 
showed that most of the tested compounds 
exhibited considerable bacterial and fungal 
inhibition performance compared to refer-
ence drugs. In general, most of the synthe-
sized compounds have a tendency to be ef-
fective against the Gram-negative bacteria 
with IZ value ~ 25 mm. The acetamide de-
rivatives (4a-g) showed strong inhibitory ac-
tivity against all tested microorganisms ex-
cept mycobacterium with the exception of 
4e. In contrast, acyl compounds 5a-f exhibit-
ed good inhibitory activity with IZ around 
20 mm especially Gmve (S.P and B.S), Gm-
ve, fungal types, and more activity against 
mycobacterium. The derivatives 6a-c 
showed comparable inhibitory activity (IZ ~ 
22 mm) against Gm+ve, Gm-ve, fungi, and 
mycobacterium. Among above mention 
compounds, 4c-i were found to be more ef-
fective against Gm-ve, Gm+ve, fungi, and 
TB by MIC 0.49 to 7.81 µg/mL compared to 
reference drugs with the attention given for 
compound 4g which showed the highest po-
tency. While some derivatives 5c-e exhibited 
reasonable potency against Gm+ve, Gm-ve, 
and fungi with MIC range 0.98 to 15.63 
µg/ml. Only one of alkynyl derivatives 6c 
showed antibacterial and antifungal activity 
with MIC range 0.98-1.95 µg/mL while it 
showed MIC 31.25 µg/mL against TB com-
pared to MIC 1.95 µg/ml for IZD (Table 3 
and Figure 7). Finally, the investigation of 
the antimicrobial activity of the novel deriva-
tives showed that some derivatives are more 
or equal potency to reference drugs against 
gm-ve bacteria, Gm+ve and fungi, and few 
derivatives (4g, 5c and d) with very strong 
antimycobacterial activity. It is worth men-
tioning that all compounds screened for the 
MIC values showed no activity against can-
dida albicans and pseudomonas aeruginosa 
(Table 3). 
 
 
Figure 6: Heatmap of inhibition zone data. 
The antimicrobial activity of the novel synthe-
sized compounds are shown and IZ data are 
color coded 
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Table 2: Antimicrobial activity of synthetic compounds (Inhibition Zone, IZ, mm) (10 mg/mL in DMSO) 
based on well diffusion assay 
Cps. Inhibition Zone Diameter (mm) 
Gm+ve Gm-ve Fungi MB 
S.P B.S S.A P.A E.C S.T A.F S.R G.C C.A TB 
3 16.2 13.1 12.3 14.5 12.5 14.1 NA 13.5 11.5 14.2 NA 
4a 13.6 16.4 12.4 15.7 17.3 16.3 NA 18.2 15.4 16.3 NA 
4b 17.3 17.9 13.6 13.4 16.2 15.4 NA 14.2 13.6 16.3 NA 
4c 22.4 21.3 20.6 22.4 22.6 20.1 NA 18.2 17.3 15.4 NA 
4d 24.2 23.6 21.3 24.6 25.1 20.3 NA 22.4 19.3 20.1 NA 
4e 20.4 22.6 19.8 24.9 26.4 21.3 NA 24.3 20.8 20.3 62.5 
4f 18.7 21.3 20.2 21.2 21.9 18.6 NA 20.1 18.3 21.3 NA 
4g 21.3 22.1 20.3 20.3 21.2 20.6 NA 21.2 18.3 18.6 NA 
4h 21.9 21.2 20.1 21.6 22.2 19.6 NA 16.9 16.4 20.6 NA 
4i 18.2 17.6 16.1 15.6 17.1 17.9 13.6 11.4 NA 19.6 NA 
5a 19.4 18.1 16.9 16.3 18.2 18.6 14.7 12.6 NA NA 60.24 
5b 13.6 16.4 12.4 13.2 15.7 17.3 18.2 15.4 NA NA 80.34 
5c 17.3 17.9 13.6 11.2 13.4 16.2 14.2 13.6 NA NA 81.63 
5d 22.4 21.3 20.6 21.3 22.4 22.6 18.2 17.3 NA 16.1 53.42 
5e 24.2 23.6 21.3 22.4 24.6 25.1 22.4 19.3 NA 16.9 NA 
5f 20.4 22.6 19.8 23.4 24.9 26.4 24.3 20.8 NA 12.4 NA 
6a 23.8 32.4 26.2 18.3 21.2 21.9 20.1 18.3 NA 13.6 82.45 
6b 21.1 22.1 19.4 18.4 20.3 21.2 21.2 18.3 NA 20.6 76.35 
6c 15.2 17.3 17.7 15.6 17.1 17.9 16.9 16.4 NA NA NA 
AmP 23.8 32.4 26.2 - - - - - -  - - 
CPX  -  -  - 22.3 25.3 27.4 - - -  -  - 
AmB - - -  -  -  23.7 19.7 28.7 25.4  - 
IZD - - -  -  -  -  -  -  -  - 83.2 
Mean zone of inhibition (IZ) expressed as mm from at least three experiments (Mean ± SE, SE range 0.07 to 1.2); (NA) means 
no activity,(-) means not tested. S.P (Streptococcus Pneumoniae), B.S (Bacillus Subtilis), S.A (Staphylococcus Aureus), P.A 
(Pseudomonas Aeruginosa), E.C (Escherichia Coli), S.T (Salmonella Typhimurium), AF (Aspergillus Fumigatus), SR (Syn-
cephalastrum Racemosum), GC (Geotricum Candidum), CA (Candida albicans), and MB (Mycobacterium tuberculosis). AmP, 
stands to ampicillin; CPX, ciprofloxacin; AmP, amphotricin B; IZD, isoniazide. 
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Table 3: Antimicrobial activity of synthetic compounds (Minimum inhibitory concentration, MIC, 
µg/mL). 
Cps. Minimum inhibitory concentration (MIC, µg/mL) 
Gm+ve Gm-ve Fungi TB 
S.P B.S S.A P.A E.C S.T A.F S.R G.C C.A MT 
4c 3.9 1.95 1.95 NA 7.81 1.95 3.9 7.81 1.95 NA NA 
4f 7.81 1.95 3.9 NA 3.9 1.95 31.25 1.95 15.63 NA NA 
4g 0.49 0.49 0.98 NA 0.49 0.49 0.98 0.49 0.49 NA 1.95 
4h 3.9 0.49 3.9 NA 0.98 0.49 0.98 0.49 0.98 NA 3.9 
4i 3.9 1.95 1.95 NA 3.9 1.95 1.95 3.9 0.98 NA NA 
5c 15.63 0.98 3.9 NA 1.95 0.98 3.9 0.98 1.95 NA 1.95 
5d 31.25 3.9 31.25 NA 7.81 3.9 3.9 3.9 3.9 NA 1.95 
5e 3.9 1.95 3.9 NA 3.9 1.95 3.9 31.25 7.81 NA 15.63
6c 1.95 0.95 1.95 NA 1.95 0.98 1.95 7.80 1.95 NA 31.25
AmP 0.98 0.24 0.49 - - - - - NA  - 
CPX  -  -  - 0.99 0.49 0.46 - - NA   - 
AmB - - -  -  -  - 2.8 3.9 0.49 0.49  - 
IZD - - -  -  -  -  -  -  -  1.95 
Mean Minimum Inhibitory Concentration (MIC) in µg/mL from at least three experiments; (NA) means no activity, (-) means not 
tested. S.P (Streptococcus Pneumoniae), B.S (Bacillus Subtilis), S.A (Staphylococcus Aureus), P.A (Pseudomonas Aerugino-
sa), E.C (Escherichia Coli), S.T (Salmonella Typhimurium), AF (Aspergillus Fumigatus), SR (Syncephalastrum Racemosum), 
GC (Geotricum Candidum), CA (Candida albicans), and MT(Mycobacterium tuberculosis). AmP, stands to ampicillin; CPX, 
ciprofloxacin; AmP, amphotricin B; IZD, isoniazide. 
 
 
 
 
 
Figure 7: Heatmap of MIC data. The antimicro-
bial activity of the novel synthesized compounds 
are shown and MIC data are color coded 
 
 
4.2 Molecular modeling 
Docking studies 
Molecular docking was used to clarify 
the binding mode of the compounds to pro-
vide straightforward information for further 
structural optimization. In order to investi-
gate the mechanism of antibacterial and anti-
TB activity performance of tested com-
pounds, a detailed intermolecular interaction 
between the synthesized compounds and bio-
logical targets was analyzed through applica-
tion of molecular docking studies on the 
crystal structure of M. tuberculosis enoyl re-
ductase (InhA) complexed with 1-cyclo-
hexyl-N-(3,5-dichlorophenyl)-5-oxopyrroli-
dine-3-carboxamide (PDB ID 4TZK, 1.62 Å 
X-ray resolution) and the crystal structure of 
E. coli topoisomerase II DNA gyrase B 
complexed with Clorobiocin (PDB code 
1KZN, 2.3 Å X-ray resolution). Four com-
pounds with good activity profile were 
docked into both the active sites of ENR and 
DNA gyrase as shown in Figure 8. The pre-
dicted binding energies of the compounds 
are listed in Table 4. The interaction of com-
pound 4g with the DNA gyrase enzyme de-
picted in Figure 8A shows that C=O of 
phthalimide ring binds indirectly through 
H2O molecule (2.62 Å) by hydrogen bonding 
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to Asp49 residue. However, Arg76 amino 
acid in pocket stabilizes phthalimide ring 
though aromatic stacking effect. Stable triple 
hydrogen bonds are formed among the 
COOH moiety and Asn46 and Val120 resi-
dues by distances 2.42, 2.82, and 2.85 Å re-
spectively. The ethyl group as well is tolerat-
ed by Van der Waals' interaction through 
Ile90 residue. The behavior of 4g compound 
in ENR pocket are depicted in Figure 8B that 
shows that the phthalimide ring was stabi-
lized in the active site through hydrogen 
bonding to Thr196 via H2O molecule (3.07 
Å), hydrogen bonding via C=O to Tyr158 
residue (2.79 Å), and hydrophobic aromatic 
interaction to Met103 amino acid residue. 
The side chain formed stable hydrogen bond 
with Ser94 (2.95 Å) via OH of COOH. 
Moreover, ethyl group accommodates hy-
drophobic pocket through interaction with 
Met147 residue. The 5c compound was 
docked into ENR pocket as depicted in Fig-
ure 9A that shows the phthalimide ring is 
tolerated by hydrophobic binding pocket 
formed of Met103, Met161, Met98, and 
Gly96 residues. In addition, hydrogen bond-
ing interaction is formed between C=O 
phthalimide and Tyr158 with 2.52 Å dis-
tance. The linker C=O stabilizes the com-
pound in the pocket via hydrogen bonding 
interaction with Lys165 with 3.1 Å. More-
over, N-CH3 of piperazine fragment formed 
stable hydrogen bond with Gly14 residue 
(3.17 Å). We docked also compound 5d in 
the pocket of ENR (Figure 9B) that exhibits 
the same binding mode as compound 5c 
does. It shows tolerance of phthalimide ring 
to hydrophobic pocket formed of Met103, 
Ile202, and Met199 residues. Moreover, 
C=O linker showed hydrogen bonding inter-
action with Lys165 residue (2.82 Å). A triple 
stable hydrogen bonds were formed among 
the two C=O groups and N-pyridine ring and 
H2O, Tyr158 residues (2.86, 2.62, and 2.81 
Å) respectively. In conclusion, based upon 
modeling, it is clear that these compounds 
have ability to inhibit these enzymes and 
hence this could explain their antimicrobial 
and antimycobacterial activities. 
 
 
 
Figure 8: Binding data of target compounds. 
(A) 2D figure of the docked conformation of the 
most active compound 4g in ATP binding site of 
DNA gyrase enzyme exhibiting the correspond-
ing amino acid residues and types of interac-
tions. (B) 2D figure of the docked conformation 
of the most active compound 4g in the binding 
site of ENR enzyme revealing the essential ami-
no acid residues and types of interactions. (C) 
Structure surface of the enzyme pocket with 
bound 4g in ATP the active site of DNA gyrase. 
The binding pocket is shown as a surface with 
color-coded features: H-bonding (magenta), hy-
drophobic (green), mild hydrophilic (blue) 
A 
B 
C 
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Figure 9: Binding data of target compounds. 
(A) 2D image of the docked conformation of the 
most active compound 5c in ATP binding site of 
ENR enzyme revealing the essential residues 
and types of interactions. (B) 2D image of the 
docked conformation of the most active com-
pound 5d in the binding site of ENR enzyme re-
vealing the essential residues and types of inter-
actions 
 
 
 
Prediction of drug-likeness and ADME 
properties 
The planning for discovery of novel drug 
candidates for oral use, the bioavailability 
and proper delivery are considered to be es-
sential (Tingjun and Xiaojie, 2004). About 
one-third of invented drugs fail during de-
velopment processes due to their unreasona-
ble pharmacokinetic profiles (van de 
Waterbeemd and Gifford, 2003). Hence, a 
computational analysis for ADME properties 
prediction of the synthesized molecules was  
Table 4: Binding energy (dG) data of target 
compounds in both DNA-gyrase and M. 
tuberculosis enoyl reductase (ENR) enzymes. 
Cp. Binding energy (dG) 
DNA-Gyrase M. tuberculosis  
enoyl reductase 
3 -9.9 -9.5 
4a -10.3 -11.8 
4b -11.5 -14.1 
4c -12.3 -12.6 
4d -9.9 -11.4 
4e -10.1 -11.4 
4f -10.2 -13.9 
4g -11.2 -13.5 
4h -10.7 -14.4 
4i -11.8 -14.1 
5a -12.1 -13.1 
5b -11.8 -11.8 
5c -11.7 -11.9 
5d -10.8 -11.2 
5e -11.4 -10.1 
5f -11.2 -10.1 
6a -9.5 -9.6 
6b -10.1 -9.4 
6c -10.3 -9.8 
 
done by calculation factors of lipophilicity, 
topological polar surface area (TPSA), ab-
sorption (% ABS) and rule of five parame-
ters (Lipinski et al., 2001). A toolkit of 
Molinspiration (Peduto et al., 2011) working 
online was used. Table 5 represents a calcu-
lated absorption percentage (% ABS), topo-
logical polar surface area (TPSA) and 
Lipinski parameters of the compounds. Ab-
sorption percent (% ABS) was measured us-
ing the equation: % ABS=109−(0.345× 
TPSA) (Zhao et al., 2002). Polar surface ar-
ea, together with lipophilicity, is an im-
portant property of a molecule in transport 
across biological membranes. As indicator, 
too high TPSA values give rise to a poor bi-
oavailability and absorption of a drug. Based 
upon mentioned above, calculated percent-
ages of absorption for tested compounds 
ranged between 81 and 96 %. Number of 
N
O
O
N
O
N
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Ala
22
Ser
94Gly96
Phe
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Met
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Met
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Tyr
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Lys
165
H2O
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3
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3
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6
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hydrogen bond donors was constant for all of 
the compounds 3-8, and number of hydrogen 
bond acceptors varied from 4 to 5. In gen-
eral, investigation of Lipinski parameters of 
the synthesized compounds showed that all 
phthalimide derivatives might be considered 
as drug-like candidates for novel antimicro-
bial and anti-tuberculosis agents, as they 
obeyed the rule of five without any viola-
tions. 
 
5. CONCLUSIONS 
The biological importance of phthalimide 
scaffold and the study of some reported N-
phthalimide based products have promoted 
us for design of novel antimicrobial and an-
timycobacterial agents with high potency 
and multiple target affinity. Different syn-
thetic routes to these novel N-aryl or alkynyl 
phthalimide derivatives (4a-I, 5a-f, and 6a-
c) have been successfully carried out. The 
resulted products were screened for measur-
ing their antimicrobial activity against six 
bacteria, four fungi, and one mycobacterium 
strains. The activity data shows that most of 
the novel compounds have potent antibacte-
rial and antimycobacterial activities com-
pared to reference drugs. Their inhibition 
zones (IZ) cover a good range of activity, 18-
25 mm with corresponding minimum inhibi-
tory concentrations (MIC) nearly equal to 
0.49 to 31.25 µg/mL. Docking experiments 
and structure-activity relationship analysis 
are reported for explaining their biological 
data. Finally, certain N-phthalimide deriva-
tives of various structures were synthesized 
and offered good antimicrobial and antimy-
cobacterial activities with good DNA-gyrase 
and ENR enzymes targets affinity. 
 
 
Table 5: Predicted ADME, Lipinski parameters and molecular properties of the synthesized com-
pounds 
Cop. Mwt n-ON n-OHNH logS logP(o/w) TPSA %ABS 
3 147.13 3 1 -2.04 0.87 46.2 93.1 
4a 294.31 5 1 -3.88 1.99 66.5 86.1 
4b 328.76 5 1 -4.61 2.58 66.5 86.1 
4c 310.31 6 2 -3.51 1.68 86.7 79.1 
4d 324.34 6 1 -3.93 1.94 75.7 82.9 
4e 308.34 5 1 -4.35 2.28 66.5 86.1 
4f 312.3 5 1 -4.17 2.14 66.5 86.1 
4g 290.27 7 2 -2.63 0.78 104 73.1 
4h 304.3 7 2 -2.83 1.14 104 73.1 
4i 318.33 7 2 -3.66 1.66 104 73.1 
5a 379.39 6 0 -5.76 3.89 80.8 81.1 
5b 329.38 5 0 -5.49 3.43 71.5 84.3 
5c 273.29 6 0 -2.10 0.41 60.9 88 
5d 286.67 5 0 -3.88 2.51 67.3 85.8 
5e 286.2 8 0 -4.94 1.57 113 70 
5f 241.2 5 0 -3.84 1.43 67.6 85.7 
6a 199.21 3 0 -2.74 1.47 37.4 96.1 
6b 213.24 3 0 -2.94 1.91 37.4 96.1 
6c 213.24 3 0 -3.7 2.42 37.4 96.1 
% ABS: Percentage of absorption, TPSA: topological polar surface area, n-ON: number of hydrogen bond acceptors, n-OHNH: 
number of hydrogen bond donors, logS: solubility coefficient. Calculations were performed using Molinspiration online property 
calculation toolkit (http://www.molinspiration.com). 
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